A: Northern Kentucky offers biomedical companies a fully operational wet lab incubator (LifeSciKY, opened December 2025), a $125 million Commonwealth Center for Biomedical Excellence under construction (broke ground June 2026), and an established cluster of CROs and research companies including Thermo Fisher Scientific’s PPD division (which has invested over $106 million across two NKY expansions), CTI Clinical Trial and Consulting Services, Gravity Diagnostics, and Bexion Pharmaceuticals. Kentucky’s SBIR-STTR match program effectively doubles federal R&D funding for qualifying companies. The region has a 2.3-million-person metro patient population, 25+ universities within 75 miles, and industrial electricity costs 11% below the national average. BE NKY Growth Partnership provides no-cost site selection support.